Meeting
2023 ASCO Annual Meeting
Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.
Authors
A. Dimitrios Dimitrios Colevas
Stanford Cancer Center, Stanford, CA
A. Dimitrios Dimitrios Colevas , Michelle A. Rudek , Caroline Even , Victor Ho-Fun Lee , Maura L. Gillison , Saad A. Khan , Rong Lu , Elizabeth Winters , Savanna Biedermann , Steven Lai , Troy Messick
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04925544
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6035)
DOI
10.1200/JCO.2023.41.16_suppl.6035
Abstract #
6035
Poster Bd #
27
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.
First Author: Xuewen Ma
Poster
2023 ASCO Annual Meeting
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.
First Author: Kristoffer Staal Rohrberg
Poster
2023 ASCO Annual Meeting
Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects.
First Author: Todd Shearer
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: John D. Powderly